Other languages Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 10:02:49 2024-05-20 am EDT			5-day change	1st Jan Change
6,166 ^ILa	+1.75%		-1.20%	+61.70%

May. 17	Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	MT
May. 15	Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	May. 17
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	May. 15
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024	May. 15
En Direct des Marchés : Sabadell, TotalEnergies, Airbnb, ARM, Medincell, Nexi...	May. 09
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	May. 08
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed	May. 08
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	May. 08
Sector Update: Health Care	May. 08
Teva Pharmaceutical Industries Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed	May. 08
Teva Pharm Q1 profit falls short of estimates, revenue gains	May. 08
Teva Pharmaceutical Industries Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Teva Pharmaceutical Industries Limited Reaffirms Earnings Guidance for the Full Year 2024	May. 08
HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor	May. 01
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	Apr. 30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	Apr. 30
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	Apr. 30
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT